ARTICLE | Clinical News

Vyvanse: Phase IV data

September 15, 2014 7:00 AM UTC

Top-line data from the double-blind, international Phase IV Study SPD489-406 in 547 ADHD patients aged 13-17 years showed that once-daily 70 mg oral Vyvanse led to a 25.4 point reduction in mean ADHD-RS-IV total score from baseline to week 6, the primary endpoint, vs. a 22.1 point reduction for once-daily 72 mg oral Concerta methylphenidate (p=0.0013). Patients in the placebo arm had a 17 point reduction on the endpoint. ...